CX-4945

Phase 2Small molecule

SSenhwa Biosciences, Inc.

CX-4945 is one of 168 small molecule programs targeting Basal Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

167

Competitors

Pipeline

Status by Indication[3][1]

Indication

Basal Cell CarcinomaActive, not recruiting

PneumoniaActive, not recruiting

CholangiocarcinomaActive, not recruiting

Multiple MyelomaActive, not recruiting

MedulloblastomaActive, not recruiting

Basal Cell CarcinomaPhase 1

Active, not recruiting

PneumoniaPhase 2

Active, not recruiting

CholangiocarcinomaPhase 1/Phase 2

Active, not recruiting

Multiple MyelomaPhase 1

Active, not recruiting

MedulloblastomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

CX-4945

SSenhwa Biosciences, Inc.

Phase 2

1 2

Prolia

Amgen

Preclinical

5 3

Eliquis

Bristol-Myers Squibb

Preclinical

3 4

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 5

Adriamycin

GGynecologic Oncology Group

Preclinical

9 6

Nolvadex

AstraZeneca

Preclinical

1 7

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 8

Intron a

Systemic Therapy

1 10

Abecma

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Unknown status·CCylene Pharmaceuticals·Phase 1·NCT01199718·22 enrolled

Oral1 trial

Dose-escalation Study of Oral CX-4945

Unknown status·CCylene Pharmaceuticals·Phase 1·NCT00891280·55 enrolled

Medulloblastoma1 trial

Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Terminated·PPediatric Brain Tumor Consortium·Phase 1/2·NCT03904862·21 enrolled

Cholangiocarcinoma1 trial

Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma

Completed·SSenhwa Biosciences, Inc.·Phase 1/2·NCT02128282·127 enrolled

Basal Cell Carcinoma1 trial

Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)

Completed·SSenhwa Biosciences, Inc.·Phase 1·NCT03897036·25 enrolled

2 more indications

Pneumonia1 trial

CX-4945 in Viral Community Acquired Pneumonia

Terminated·SSenhwa Biosciences, Inc.·Phase 2·NCT06202521·45 enrolled

Unspecified1 trial

A Study of Silmitasertib (CX-4945) in Healthy Subject

Completed·SSenhwa Biosciences, Inc.·Phase 1·NCT05817708·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for CX-4945. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CX-4945 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CX-4945. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Senhwa Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSenhwa Biosciences, Inc.

CX-4945

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma1 trial

Oral1 trial

Medulloblastoma1 trial

Cholangiocarcinoma1 trial

Basal Cell Carcinoma1 trial

Pneumonia1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News